Entity

Time filter

Source Type


Polyzos S.A.,Harvard University | Makras P.,251 Hellenic Air Force | Efstathiadou Z.,Hippokration General Hospital of Thessaloniki | Anastasilakis A.D.,424 General Military Hospital
Expert Opinion on Investigational Drugs | Year: 2015

Introduction: Intermittent parathyroid hormone (PTH) administration, acting through multiple signaling pathways, exerts an osteoanabolic effect on the skeleton that surpasses the effect of other antiosteoporotic agents. However, its efficacy is limited by the coupling effect and relatively common adverse events. Thus, the development of more sophisticated PTH receptor analogs seems imperative. Areas covered: In this review, the authors summarize the role of PTH signaling pathway in bone remodeling. The authors also summarize investigational analogs targeting this pathway, which may be potential treatments for osteoporosis. Expert opinion: β-arrestins are multifunctional cytoplasmic molecules that are decisive for regulating intracellular PTH signaling. Recently, in preclinical studies, arrestin analogs have achieved the anabolic bone effect of PTH without an accompanying increase in bone resorption. However, it is not yet known whether these analogs have adverse effects and there are no clinical data for their efficacy to date. On the other hand, several molecules derived either from PTH and PTH-related protein (PTHrP) molecules have been developed. Alternative routes of PTH 1-34 delivery (oral, transdermal), the PTH analog ostabolin and the N-terminal PTHrP analogs PTHrP 1-36 and abaloparatide, have recently been or are currently being tested in clinical trials and are more likely to become available for use in the near future. © 2015 Informa UK, Ltd. Source


Papathomas T.G.,Hippokration General Hospital of Thessaloniki | Papathomas T.G.,Erasmus University Rotterdam | Venizelos I.,Hippokration General Hospital of Thessaloniki | Dunphy C.H.,University of North Carolina at Chapel Hill | And 9 more authors.
Human Pathology | Year: 2012

Composite lymphoma is a rare circumstance in which 2 or more distinct types of lymphoma occur in a single anatomical location. Although composite lymphoma has been increasingly identified with the advent of molecular genetic techniques, this topic has only rarely been a specific focus of the medical scientific literature. In this review, we focus on mantle cell lymphoma occurring as a major pathologic component of composite lymphoma and emphasize the clinicopathologic features of these tumors and associated biologic implications. To date, 26 cases of composite lymphoma including a component of mantle cell lymphoma have been previously published. Issues of clonal relatedness between the individual lymphoma components and emerging biologic implications as well as potential diagnostic pitfalls are evaluated. © 2012 Elsevier Inc. All rights reserved. Source


Patsiaoura K.,Hippokration General Hospital of Thessaloniki | Anagnostou E.,Hippokration General Hospital of Thessaloniki
Auris Nasus Larynx | Year: 2010

Intramuscular myxoma is an uncommon benign soft tissue neoplasm and a distinct histopathological entity within the heterogeneous group of myxomas. The most common localizations are the gluteal muscles and the muscles of the thigh. We report on a case of a myxoma within the mimetic muscles of the nasal and mouth region in a 52-year-old man. The tumor was surgically removed and the patient is free of recurrence or complications 8 months after treatment. The clinical and pathologic features of this lesion are presented. The head and neck region is an uncommon site of presentation for intramuscular myxoma with only 13 documented cases in the available literature. To the very best of our knowledge, there is no report of this neoplasm located within the nasal and oral mimetic muscles. © 2009 Elsevier Ireland Ltd. All rights reserved. Source


Venizelos I.,Hippokration General Hospital of Thessaloniki | Papathomas T.G.,Hippokration General Hospital of Thessaloniki | Papathanasiou M.,Aristotle University of Thessaloniki | Cheva A.,Hippokration General Hospital of Thessaloniki | And 2 more authors.
Survey of Ophthalmology | Year: 2010

Castleman disease is a quite uncommon lymphoproliferative disorder usually occurring in the lymph nodes. Rarely, Castleman disease develops in an extranodal anatomic location. We report on the first biopsy-proven case of multicentric plasma cell type of Castleman disease involving the orbital areas in a human herpes virus 8 (HHV-8)-unassociated/ human immunodeficiency virus (HIV)-seronegative 70-year-old man suffering from Parkinson disease. The diagnosis was established on the basis of morphologic, immunophenotypic, and molecular findings of a lymph node and orbital soft tissue biopsy. We additionally provide a review of all previously published cases of Castleman disease with an orbital involvement, discussing the distinctive characteristics and potential associations with regard to their counterparts at other sites. Although Castleman disease involving the orbit is an exceptionally rare occurrence that may present initially with ocular signs and symptoms, this should be included in the complete differential diagnosis of orbital mass lesion. © 2010 Elsevier Inc. Source


Cappellini M.D.,University of Milan | Bejaoui M.,Center National Of Greffe Of Moelle Osseuse | Agaoglu L.,Istanbul University | Canatan D.,Suleyman Demirel University of Turkey | And 14 more authors.
Blood | Year: 2011

Patients with β-thalassemia require lifelong iron chelation therapy from early childhood to prevent complications associated with transfusional iron overload. To evaluate long-term efficacy and safety of once-daily oral iron chelation with deferasirox, patients aged ≥ 2 years who completed a 1-year, phase 3, randomized trial entered a 4-year extension study, either continuing on deferasirox (deferasirox cohort) or switching from deferoxamine to deferasirox (crossover cohort). Of 555 patients who received ≥ 1 deferasirox dose, 66.8% completed the study; 43 patients (7.7%) discontinued because of adverse events. In patients with ≥ 4 years' deferasirox exposure who had liver biopsy, mean liver iron concentration significantly decreased by 7.8 ± 11.2 mg Fe/g dry weight (dw; n = 103; P < .001) and 3.1 ± 7.9 mg Fe/g dw (n = 68; P < .001) in the deferasirox and crossover cohorts, respectively. Median serum ferritin significantly decreased by 706 ng/mL (n = 196; P < .001) and 371 ng/mL (n = 147; P < .001), respectively, after ≥ 4 years'exposure. Investigator-assessed, drug-related adverse events, including increased blood creatinine (11.2%), abdominal pain (9.0%), and nausea (7.4%), were generally mild to moderate, transient, and reduced in frequency over time. No adverse effect was observed on pediatric growth or adolescent sexual development. This first prospective study of long-term deferasirox use in pediatric and adult patients with β- thalassemia suggests treatment for ≤ 5 years is generally well tolerated and effectively reduces iron burden. This trial was registered at www.clinicaltrials-.gov as #NCT00171210. © 2011 by The American Society of Hematology. Source

Discover hidden collaborations